West Pharmaceutical Services Inc.（WST）股票——这是一门好生意吗？

Just reported

Q3 2026 results

From West Pharmaceutical Services's results release of 2026年10月29日; its quarterly report has since been filed.

Revenue
Actual
US$874.5M
+8.7% y/y
+0.3% q/q
Guided
US$827.5M
midpoint
Above guide+5.7%
EPS, GAAP
Actual
US$3.02
+57% y/y
+40% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
US$267.4M
+60% y/y
+49% q/q
Guided
—
No guide given

Company outlook

Full year 2026

RevenueUS$3.41B – US$3.42B+11% y/y Raised +1.6%
EPS, adjustedUS$9.38 – US$9.48Raised +5.4%

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

The full earnings report →

Keep exploring

The themes West Pharmaceutical Services is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.